Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.  

In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 

A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.